R
Romulus Capital Management, LLC
+ Con en carteraHIND
+0.00%
Rentabilidad a 3 meses
$1.600
-0.029 (-1.84%)Al cierre
Loading chart…
- Máximo
- 1.660
- Apertura
- 1.660
- Precio medio ponderado por volumen
- 1.61
- Volumen
- 19.77K
- Capitalización
- —
- Mínimo
- 1.570
- Importe
- 31.83K
- EV/EBITDA, TTM
- -0.56
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
Análisis de IA of Vyome Holdings Inc (HIND)
MantenerCurrently, Vyome Holdings Inc (HIND) is not a good buy due to its extremely low RSI of 17.286, indicating oversold conditions, and a significant year-to-date change of -54.93%. While the analyst target suggests potential upside, the current financial instability and negative earnings reports raise concerns.
Métricas de valoración
El PER previsto actual de Vyome Holdings Inc (HIND) es 0.00, frente a su media de 5 años de -8.15.
Ballenas con HIND en cartera
Cronología de eventos
Noticias
5.009-14NewsfilterVyome Holdings Appoints New CFO Jerry Leonard
9.505-29seekingalphaVyome Holdings Reports Q1 Revenue of $31.59M
- 7.505-28Newsfilter
Vyome Partners with Impetis for JAK Inhibitors, Targeting $57B Market
- 9.503-26seekingalpha
Vyome Holdings Reports FY 2025 Financial Results
- 8.502-18Newsfilter
Vyome Publishes Preclinical Data for VT-1908
Preguntas frecuentes sobre HIND, respondidas por Alphio AI
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology. It operates in the Healthcare sector.
Currently, Vyome Holdings Inc (HIND) is not a good buy due to its extremely low RSI of 17.286, indicating oversold conditions, and a significant year-to-date change of -54.93%. While the analyst target suggests potential upside, the current financial instability and negative earnings reports raise concerns.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.